A popular ADHD medication is being pulled from shelves across the nation, leaving patients and doctors with questions and concerns. But why? It's all due to a failed lab test.
The U.S. Food and Drug Administration (FDA) has issued a recall for a generic version of the well-known ADHD medication, Vyvanse. Sun Pharmaceutical Industries Inc. voluntarily recalled their lisdexamfetamine dimesylate capsules on October 28, 2025, after they failed to meet dissolution standards in laboratory testing. This is a crucial test to ensure the medication breaks down properly in the body.
The recall affects various strengths of this stimulant medication, typically prescribed to enhance focus in ADHD patients. Interestingly, it's also used to treat Binge Eating Disorder (BED), as approved by the FDA.
The FDA has classified this as a Class II recall, suggesting potential temporary health issues. The agency noted that the capsules didn't dissolve as expected, which could impact the drug's effectiveness. However, the exact reasons for the dissolution failure remain undisclosed.
The recall includes bottles containing 100 capsules, with strengths ranging from 10 mg to 70 mg. Each strength has multiple lot numbers and expiration dates from February to May 2026. Patients can identify the recalled medication by checking the lot numbers on their medication packaging.
Here are the lot numbers and expiration dates to look out for:
- Lisdexamfetamine Dimesylate Capsules, 10 mg: AD42468 (Exp. 02/28/26), AD48705 (Exp. 04/30/26)
- Lisdexamfetamine Dimesylate Capsules, 20 mg: AD42469 (Exp. 02/28/26), AD48707 (Exp. 04/30/26)
- Lisdexamfetamine Dimesylate Capsules, 30 mg: AD42470 (Exp. 02/28/26), AD48708 (Exp. 04/30/26)
- Lisdexamfetamine Dimesylate Capsules, 40 mg: AD48709 (Exp. 04/30/26), AD50894 (Exp. 05/31/26)
- Lisdexamfetamine Dimesylate Capsules, 50 mg: AD48710 (Exp. 04/30/26), AD50895 (Exp. 05/31/26)
- Lisdexamfetamine Dimesylate Capsules, 60 mg: AD48711 (Exp. 04/30/26), AD50896 (Exp. 05/31/26)
- Lisdexamfetamine Dimesylate Capsules, 70 mg: AD48712 (Exp. 04/30/26), AD50898 (Exp. 05/31/26)
And here's where it gets tricky: The FDA hasn't provided clear instructions for patients with the recalled medication. If you have these capsules, it's recommended to contact your pharmacist or doctor for advice on what to do next.
This recall highlights the importance of rigorous testing and the potential impact on patient health. It also raises questions about the effectiveness of generic medications compared to their brand-name counterparts. Do you think generic medications are as reliable? Share your thoughts below!
